Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinzadeh-Attar MJ. Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. BMJ Open. 2017 Jul 1;7(7):e016914.
Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, Hosseinzadeh-Attar MJ. The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial. Nanomedicine Journal. 2018;5(2):67–76.
Daneshi-Maskooni M, Keshavarz SA, Qorbani M, Mansouri S, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. Nutrition & metabolism. 2018 Dec;15(1):63.
Daneshi-Maskooni M, Keshavarz SA, Mansouri S, Qorbani M, Alavian SM, Badri-Fariman M, Jazayeri-Tehrani SA, Sotoudeh G. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial. Trials. 2017 Dec;18(1):260.
Ayada C, Toru Ü, Korkut Y. Nesfatin-1 and its effects on different systems. Hippokratia. 2015;19:4.
Başar O, Akbal E, Köklü S, et al. A novel appetite peptide, nesfatin-1 in patients with the non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2012;72:479–83.
Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–54.
Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.
Verma SK, Jain V, Singh DP. Effect of greater cardamom (Amomum subulatum Roxb.) on blood lipids, fibrinolysis and total antioxidant status in patients with ischemic heart disease. Asian Pacific J Trop Dis. 2012;2:S739–43.
Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology. 1990;99:1408–13.
The lab tests online. Laboratory methods used for medical lab testing (enzyme-linked immunosorbent assay (ELISA)) [Internet]. 2012. [cited 26 Feb 2017]. Available from: https://labtestsonline.org/understanding/features/methods/start/2/. Accessed 26 Feb 2017.
Jazayeri S, Nouri M, Pour-Ebrahim R, Fakhrzadeh H, Larijani B. Food and nutrient intake status in urban population (20–60 years) of population research center of Tehran University of Medical Sciences. Iran J Diab Lipid. 2005;1(3):81–9 [in Farsi].
Qaffarpour M, Houshyar-Rad A, Kianfar H. Guides of home scales, conversion coefficients and percentage of Iranian foods. Tehran: Agricultural Sciences Publication; 2000. [in Farsi]
The IPAQ group. International Physical Activity Questionnaire [Internet]. 2017. [cited 26 Feb 2017]. Available from: https://sites.google.com/site/theipaq/.
Booth ML, Ainsworth BE, Pratt MI, Ekelund U, Yngve AG, Sallis JF, Oja PE. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;195(9131/03):3508–1381.
Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, et al. Curcumin extract for prevention of type 2 diabetes. Diabetes Care. 2012;35:2121–7.
Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Efficacy and safety of phytosomal curcumin in non-alcoholic fatty liver disease: a randomized controlled trial. Drug research. 2017 Apr;67(04):244–51.
Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. 2014 Feb 1;25(2):144–50.
Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, Sahebkar A. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology. 2017 Feb 1;25(1):25–31.
Hewlings SJ, Kalman DS. Curcumin: a review of its’ effects on human health. Foods. 2017 Oct 22;6(10):92.
Lizana P, Galdames M, Rodrigo R. Oxidative stress and endoplasmic reticulum stress as potential therapeutic targets in non-alcoholic fatty liver disease. Reactive Oxygen Species. 2017;4(10):266–74.
Navekar R, Rafraf M, Ghaffari A, Asghari-Jafarabadi M, Khoshbaten M. Turmeric supplementation improves serum glucose indices and leptin levels in patients with nonalcoholic fatty liver diseases. J Am Coll Nutr. 2017 May 19;36(4):261–7.
Kocaadam B, Şanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2889–95.
Jin T, Song Z, Weng J, Fantus IG. Curcumin and other dietary polyphenols: potential mechanisms of metabolic actions and therapy for diabetes and obesity. American Journal of Physiology-Endocrinology and Metabolism. 2018;314(3):E201–5. https://doi.org/10.1152/ajpendo.00285.2017.
Hariri M, Haghighatdoost F. Effect of curcumin on anthropometric measures: a systematic review on randomized clinical trials. J Am Coll Nutr. 2018 Jan 8;37(3):215–22. https://doi.org/10.1080/07315724.2017.1392263.
Shen P, Han Y, Cai B, Wang Y. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep and Breathing. 2015 May 1;19(2):515–22.
Zhang DW, Fu M, Gao SH, Liu JL. Curcumin and diabetes: a systematic review. Evid Based Complement Alternat Med. 2013;2013.
Syabaniarti AN. The Relationship between Body Mass Index (BMI) and Waist Circumference (WC) to fasting blood glucose level based on the medical check-up result of PT. X Regional Jakarta Employees Year 2016. 2nd International Seminar on Global Health (ISGH); 2018: 306–312. http://repository.stikesayani.ac.id/index.php/isgh2/article/view/66.
Dong J, Xu H, Wang PF, Cai GJ, Song HF, Wang CC, Dong ZT, Ju YJ, Jiang ZY. Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One. 2013 Dec 31;8(12):e83397.
Kim SH, Ahn M, Jung IA, Jeon YJ, Cho WK, Cho KS, Park SH, Jung MH, Suh BK. The relation of serum Nesfatin-1 level with anthropometric and metabolic parameters in Korean children and young adolescents. ESPE Abstracts 2015; 84: P2–375. http://abstracts.eurospe.org/hrp/0084/hrp0084p2-375.htm.
Abaci A, Catli G, Anik A, Kume T, Bober E. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes. 2013 May 1;14(3):189–95.
Hamedani NK, Hosseinzadeh-Attar MJ, Hosseini M. The correlation between nesfatin-1 and blood pressure in healthy normal weight and obese adults. International Research Journal of Applied and Basic Sciences. 2014;8(4):398–400.
de Meloa IS, dos Santosb AF, Buenoc NB. Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2017 Sep 18;128:137–44. https://doi.org/10.1016/j.phrs.2017.09.010.
Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Ghayour MM, Kazemi RO. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna journal of phytomedicine. 2016;6(5):567–77.
Kim HG, Lee SB, Lee JS, Kim WY, Choi SH, Son CG. Artemisia iwayomogi plus Curcuma longa Synergistically Ameliorates Nonalcoholic Steatohepatitis in HepG2 Cells. Evidence-Based Complementary and Alternative Medicine. 2017; Article ID 4390636. 9 pages. Doi: https://doi.org/10.1155/2017/4390636.
Ghorbani Z, Hekmatdoost A, Mirmiran P. Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principal constituent curcumin. International journal of endocrinology and metabolism. 2014 Oct 1;12(4):e18081.
Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M, Sahbekar A. Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial. Complementary therapies in medicine. 2017 Aug 1;33:1–5.
Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, Ghayour-Mobarhan M, Ferns GA. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res. 2013 Mar 1;27(3):374–9.
Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013 Jan 1;15(1):195–218.
S Darvesh A, B Aggarwal B, Bishayee A. Curcumin and liver cancer: a review. Curr Pharm Biotechnol. 2012 Jan 1;13(1):218–28.
Ballantyne M. The Pharmacognosy and Therapeutic Efficacy of Turmeric (Curcuma longa): A Systematic Review. Senior Honors Projects. 2017; Paper 573. http://digitalcommons.uri.edu/srhonorsprog/573
Kapakos G, Youreva V, Srivastava AK. Cardiovascular protection by curcumin: molecular aspects. Indian J Biochem Biophys. 2012 Oct;49(5):306–15.
Lopresti AL, Hood SD, Drummond PD. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol. 2012 Dec;26(12):1512–24.
Meng B, Li J, Cao H. Antioxidant and anti-inflammatory activities of curcumin on diabetes mellitus and its complications. Curr Pharm Des. 2013 Apr 1;19(11):2101–13.
Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2017 Jan 1;85:102–12.
Noorafshan A, Ashkani-Esfahani S. A review of the therapeutic effects of curcumin. Curr Pharm Des. 2013 Apr 1;19(11):2032–46.
Sahebkar A, Cicero AF, Simental-Mendía LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-α levels: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016 May 1;107:234–42.
Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. Biofactors. 2013 Jan 1;39(1):27–36.
Schlecht I, Fischer B, Behrens G, Leitzmann MF. Relations of visceral and abdominal subcutaneous adipose tissue, body mass index, and waist circumference to serum concentrations of parameters of chronic inflammation. Obesity facts. 2016;9(3):144–57.
Stepanikova I, Oates GR, Bateman LB. Does one size fit all? The role of body mass index and waist circumference in systemic inflammation in midlife by race and gender. Ethnicity & health. 2017 Mar 4;22(2):169–83.
Panahi Y, Ahmadi Y, Teymouri M, Johnston TP, Sahebkar A. Curcumin as a potential candidate for treating hyperlipidemia: a review of cellular and metabolic mechanisms. J Cell Physiol. 2018 Jan 1;233(1):141–52.
Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, Hu H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16(1):68. https://doi.org/10.1186/s12937-017-0293-y.
Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr. 2014 Jun 1;33(3):406–14.
Li ZL, Xu L, Sun XR, Guo FF, Gong YL, Gao SL. Central nesfatin-1 influences the excitability of ghrelin-responsive gastric distension neurons in the arcuate nucleus and reduces gastric motility in rats. Eur J Neurosci. 2013 Dec 1;38(11):3636–43.
Veghari G, Sedaghat M, Joshaghani H, Banihashem S, Moharloei P, Angizeh A, Tazik E, Moghaddami A, Hajian-Tilaki K, ZahedPasha Y. The association of fasting blood glucose (FBG) and waist circumference in northern adults in Iran: a population-based study. Journal of Diabetes & Metabolic Disorders 2014 Dec;13(1):2. http://www.jdmdonline.com/content/13/1/2
Ramesh N, Gawli K, Kiran Pasupulleti V, Unniappan S. Metabolic and cardiovascular actions of nesfatin-1: implications in health and disease. Curr Pharm Des. 2017 Mar 1;23(10):1453–64.
Yin Y, Li Z, Gao L, Li Y, Zhao J, Zhang W. AMPK-dependent modulation of hepatic lipid metabolism by nesfatin-1. Mol Cell Endocrinol. 2015 Dec 5;417:20–6.
Catak Z, Aydin S, Sahin İ, Kuloglu T, Aksoy A, Dagli AF. Regulatory neuropeptides (ghrelin, obestatin, and nesfatin-1) levels in serum and reproductive tissues of female and male rats with the fructose-induced metabolic syndrome. Neuropeptides. 2014 Jun 1;48(3):167–77.
Mohanna S, Baracco R, Seclén S. Lipid profile, waist circumference, and body mass index in a high altitude population. High Alt Med Biol. 2006 Sep 1;7(3):245–55.
Kang HT, Yoon JH, Kim JY, Ahn SK, Linton JA, Koh SB, Kim JK. The association between the ratio of triglyceride to HDL-C and insulin resistance according to waist circumference in a rural Korean population. Nutr Metab Cardiovasc Dis. 2012 Dec 1;22(12):1054–60.
Sengupta M, Sharma GD, Chakraborty B. Hepatoprotective and immunomodulatory properties of aqueous extract of Curcuma longa in carbon tetrachloride intoxicated Swiss albino mice. Asian Pacific journal of tropical biomedicine. 2011 Jun 1;1(3):193–9.
Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009 Jun;14(2):141–53.
Ghandadi M, Sahebkar A. Curcumin: an effective inhibitor of interleukin-6. Curr Pharm Des. 2017 Feb 1;23(6):921–31.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008 Jun 1;65(11):1631–52.
Derosa G, Maffioli P, Simental-Mendía LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016 Sep 1;111:394–404.
Jacob A, Wu R, Zhou M, Wang P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-γ Activation. PPAR Research 2007; Article ID: 89369. 5 pages. doi:https://doi.org/10.1155/2007/89369.
Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012 Jul 1;36(1):39–45.
Kolgazi M, Cantali-Ozturk C, Deniz R, Ozdemir-Kumral ZN, Yuksel M, Sirvanci S, Yeğen BC. Nesfatin-1 alleviates gastric damage via direct antioxidant mechanisms. journal of surgical research. 2015 Jan 1;193(1):111–8.
Shirvani H, Ghanbari-Niaki A, Rahmati-Ahmadabad S. Effects of endurance training and herb supplementation on tissue nesfatin-1/nucleobindin-2 and ghrelin mRNA expression. International Journal of Applied Exercise Physiology. 2017 Apr 27;6(1):71–84.
Afrin R, Arumugam S, Rahman A, Wahed MI, Karuppagounder V, Harima M, Suzuki H, Miyashita S, Suzuki K, Yoneyama H, Ueno K. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation. Int Immunopharmacol. 2017 Mar 1;44:174–82.
Bao W, Li K, Rong S, Yao P, Hao L, Ying C, Zhang X, Nussler A, Liu L. Curcumin alleviates ethanol-induced hepatocytes oxidative damage involving heme oxygenase-1 induction. J Ethnopharmacol. 2010 Mar 24;128(2):549–53.
Chi X, Yu D, Li P, Lu Q, Jiang W, Hao K. The protective effects of (1E, 6E)-1, 7-diphenylhepta-1, 6-diene-3, 5-dione, a curcumin analogue, against operative liver injury in rats. Eur J Pharm Sci. 2017 Mar 30;100:94–101.
Guo C, Ma J, Zhong Q, Zhao M, Hu T, Chen T, Qiu L, Wen L. Curcumin improves alcoholic fatty liver by inhibiting fatty acid biosynthesis. Toxicol Appl Pharmacol. 2017 Aug 1;328:1–9.